David Sallman, MD, Moffit Cancer Center, Tampa, FL, shares the findings of a Phase Ib study investigating the combination of magrolimab and azacitidine in patients with TP53-mutant acute myeloid leukemia (AML) (NCT03248479), commenting on the tolerability and efficacy of this combination in this high-risk patient group. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.